Levels of autoantibodies, unlike antibodies to all extrinsic antigen groups, fall following B cell depletion with Rituximab (Q46846243)

25 December 2017

title

Levels of autoantibodies, unlike antibodies to all extrinsic antigen groups, fall following B cell depletion with Rituximab (English)

1 reference

25 December 2017

1 reference

1 reference

Alastair J Ferraro

1 reference

25 December 2017

Mark T Drayson

series ordinal

1 reference

25 December 2017

Caroline O S Savage

series ordinal

1 reference

25 December 2017

Ian C M MacLennan

series ordinal

1 reference

25 December 2017

language of work or name

English

0 references

publication date

1 January 2008

1 reference

25 December 2017

European Journal of Immunology

published in

1 reference

25 December 2017

volume

1 reference

25 December 2017

issue

1 reference

25 December 2017

page(s)

292-298

1 reference

25 December 2017

Enrichment of anti-glomerular antigen antibody-producing cells in the kidneys of MRL/MpJ-Fas(lpr) mice

cites work

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737557

Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737557

7 January 2021

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737557

7 January 2021

An open study of B lymphocyte depletion in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737557

7 January 2021

Effective therapeutic use of rituximab in refractory Wegener's granulomatosis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737557

7 January 2021

B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737557

7 January 2021

B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737557

7 January 2021

https://api.crossref.org/works/10.1002%2FEJI.200737557

1 reference

7 January 2021

Evolution of autoantibody responses via somatic hypermutation outside of germinal centers

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737557

7 January 2021

CD40-CD40L independent Ig gene hypermutation suggests a second B cell diversification pathway in humans

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737557

7 January 2021

Humoral immunity due to long-lived plasma cells.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737557

7 January 2021

Survival of long-lived plasma cells is independent of antigen.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737557

7 January 2021

B cell depletion therapy in rheumatic disease

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737557

7 January 2021

Distinct short-lived and long-lived antibody-producing cell populations

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737557

7 January 2021

The phenotype and fate of the antibody-forming cells of the splenic foci

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737557

7 January 2021

B cell clones that sustain long-term plasmablast growth in T-independent extrafollicular antibody responses

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737557

7 January 2021

Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737557

7 January 2021

Pharmacodynamics of Rituximab in Kidney Allotransplantation

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737557

7 January 2021

Quantity and avidity of pneumococcal antibodies before and up to five years after pneumococcal vaccination of elderly persons

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737557

7 January 2021

Avidity of EBV VCA-specific IgG antibodies: distinction between recent primary infection, past infection and reactivation

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737557

7 January 2021

Predominant influence of environmental determinants on the persistence and avidity maturation of antibody responses to vaccines in infants

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737557

7 January 2021

Generation of adult-like antibody avidity profiles after early-life immunization with protein vaccines

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737557

7 January 2021

Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737557

7 January 2021

Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737557

7 January 2021

Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737557

7 January 2021

Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737557

7 January 2021

Intrinsic constraint on plasmablast growth and extrinsic limits of plasma cell survival

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737557

7 January 2021

METABOLISM OF HUMAN GAMMA MACROGLOBULINS.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737557

7 January 2021

Clinical images: B cell depletion in the appendix following rituximab treatment

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737557

7 January 2021

Effective B cell depletion with rituximab in the treatment of autoimmune diseases

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737557

7 January 2021

Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737557

7 January 2021

The effect of desensitization protocols on human splenic B-cell populations in vivo.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737557

7 January 2021

Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737557

7 January 2021

Immunogenetic analysis of the immune response to pneumococcal polysaccharide

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737557

7 January 2021

Somatic hypermutation and diverse immunoglobulin gene usage in the human antibody response to the capsular polysaccharide of Streptococcus pneumoniae Type 6B.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737557

7 January 2021

B lymphocyte maturation in Wegener's granulomatosis: a comparative analysis of VH genes from endonasal lesions

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737557

7 January 2021

Functional analysis of rheumatoid factor-producing B cells from the synovial fluid of rheumatoid arthritis patients

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737557

7 January 2021

Involvement of inducible costimulator in the exaggerated memory B cell and plasma cell generation in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737557

7 January 2021

Inflamed kidneys of NZB / W mice are a major site for the homeostasis of plasma cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737557

7 January 2021

Accumulation of plasma cells expressing CXCR3 in the synovial sublining regions of early rheumatoid arthritis in association with production of Mig/CXCL9 by synovial fibroblasts

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737557

7 January 2021

Clinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNF alpha and IL18 but not CXCL12.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737557

7 January 2021

The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737557

7 January 2021

Development and validation of a nonaplex assay for the simultaneous quantitation of antibodies to nine Streptococcus pneumoniae serotypes

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737557

7 January 2021

Identifiers

DOI

10.1002/EJI.200737557

1 reference

25 December 2017

1 reference

25 December 2017